Get expert support for food supplements registration in China, ensuring full compliance with SAMR regulations and market entry with ease. Contact us today! China Food Supplement Regulation falls under the State Administration for Market Regulation (SAMR). The responsibility is shared between the state, provincial, municipal, and county-level authorities.
Freyr provides China medical device registration and approval support for device manufacturers that includes registration, classification, NMPA legal agent/representation services for product compliance as per NMPA & CMDE regulations. China is one of the fastest-growing markets for Medical Devices, where the demand for devices is majorly met through imports.
Freyr provides China Drug Registration and Approval support for pharmaceutical manufacturers that includes product classification, registration and approval for regulatory compliance as per NMPA regulations. As the world’s best pharmaceutical manufacturing powerhouse, China offers many business opportunities for pharma manufacturers
Freyr provides End-to-End Regulatory Services in China to pharmaceuticals, Medical Device, Food Supplements, Cosmetic and Consumer Companies to comply with NMPA Regulations. Freyr is a leading Regulatory solutions provider offering comprehensive services to life sciences firms across the regulatory spectrum..
Freyr provides Brazil Drug Registration and Approval support for pharmaceutical manufacturers that includes product classification, registration and approval for regulatory compliance as per ANVISA regulations. In Brazil drug registration and Brazil regulatory drug approval process are governed by a high-quality Regulatory system that constantly updates its standards, driven by the belief that healthcare is a constitutional right.
Freyr provides Brazil medical device registration and approval support for device manufacturers that include registration, classification, INMETRO certification and Brazil Registration Holder (BRH) services for product compliance as per ANVISA regulations.
Overview The Life Sciences industry is built on innovation in terms of their constant search for new drugs, devices, and cures. Technology has become ubiquitous in driving not only scientific innovation but also in building, integrating, and managing platforms that support scientific innovation. At Freyr, we understand global Regulatory requirements management and its impact on day-to-day Regulatory decisions in strategy, submission planning, preparation, and dossier creation.
Freyr provides food regulatory services in brazil for food supplements span across product registration, classification, label, claims review, formulation review/ingredient assessment, gap analysis and dossier compilation as per ANVISA regulations for compliant market entry.
Freyr provides cosmetic product registration with ANVISA for cosmetic product registration, classification, notification, clams review, label translation, regulatory consulting, and ingredient analysis as per ANVISA regulations for compliant market entry.
Freyr Solutions provides the best drug registration process in brazil and all kind of regulatory requriements. And ensures compliance and smooth market entry with tailored solutions for the Brazilian pharmaceutical industry. Freyr is a global Regulatory leader providing services and solutions to life sciences companies. With a strong Regulatory knowledge base across 120+ countries, we support life sciences companies in their “local to global” journey.
Freyr provides Japan medical device registration and approval support for device manufacturers that includes registration, classification, MAH and D-MAH agent services for product compliance as per PMDA regulations. Though the market looks promising, the major barrier in obtaining medical device approval in Japan market is the stringent Pharmaceuticals and Medical Devices Agency (PMDA) regulations that companies must abide by.
Freyr provides Japan Drug Registration and Approval support for pharmaceutical manufacturers that includes product classification, registration and approval for regulatory compliance as per PMDA regulations. As of 2024, Japan’s pharmaceutical market has continued to grow steadily, with sales reaching $67.5 billion, further solidifying its position as the third-largest pharmaceutical market globally, following the United States and China.
